Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-336101

RESUMO

<p><b>OBJECTIVE</b>To explore the therapeutic effects of amiodarone and metoprolol, either alone or in combination, on chronic heart failure (CHF) complicated by ventricular arrhythmia.</p><p><b>METHODS</b>A total of 110 NYHA class II-III patients with CHF complicated by ventricular arrhythmia were randomly divided into amiodarone group, metoprolol group and amiodarone + metoprolol group. The therapeutic effects was evaluated at the end of the 1-year follow-up.</p><p><b>RESULTS</b>Amiodarone, metoprolol and their combination produced statistically different therapeutic effects (P<0.05). Compared with amiodarone and metoprolol used alone, amiodarone combined with metoprolol resulted in significant cardiac function improvement (P<0.05) and ventricular arrhythmia control (P<0.01). During the 1-year follow-up, the readmission rate and cardiac event rate in the amiodarone + metoprolol group were significantly lower than those in amiodarone group (P<0.01) and metoprolol group (P<0.05). The adverse reaction rates in the 3 groups were similar (P>0.05).</p><p><b>CONCLUSION</b>The combination of amiodarone and metoprolol produces better effect than amiodarone or metoprolol alone in the treatment of CHF complicated by ventricular arrhythmia.</p>


Assuntos
Adulto , Feminino , Humanos , Masculino , Antagonistas Adrenérgicos beta , Usos Terapêuticos , Amiodarona , Usos Terapêuticos , Antiarrítmicos , Usos Terapêuticos , Doença Crônica , Quimioterapia Combinada , Insuficiência Cardíaca , Tratamento Farmacológico , Metoprolol , Usos Terapêuticos , Taquicardia Ventricular , Tratamento Farmacológico , Resultado do Tratamento , Complexos Ventriculares Prematuros , Tratamento Farmacológico
2.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-310394

RESUMO

<p><b>OBJECTIVE</b>To develop a novel gene delivery vector with poly-aspartamide-glutamic acid and polyethylenimine as the backbone.</p><p><b>METHODS</b>alpha, beta-poly-(N-2-hydroxypropyl)-D, L-aspartamide-glutamic acid (PHPAG) was synthesized and low molecular weight polyethylenimine (PEI 1.8 kDa) was grafted to form PHPAG-PEI 1800. Chemical and biological characterization of the polymer was identified.</p><p><b>RESULT</b>The polymer was confirmed by (1)H-NMR, and the molecular weight was about 1.2 x 10(4). The ability of DNA binding was showed by gel retardation assay at N/P ratio of 3. 5. MTT assay showed that the polymer was non toxic in COS-7 and A293 cell lines. In vitro test demonstrated that it had high transfection efficiency in B16 and Hela cell lines.</p><p><b>CONCLUSION</b>PHPAG-PEI 1800 was successfully synthesized,which might be a potential vector for gene delivery.</p>


Assuntos
Humanos , Linhagem Celular , Técnicas de Transferência de Genes , Terapia Genética , Métodos , Ácido Glutâmico , Química , Peptídeos , Química , Polietilenoimina , Química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...